Progyny (Progyny) ROCE %

: 10.00% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Progyny's annualized ROCE % for the quarter that ended in Dec. 2023 was 10.00%.

Progyny ROCE % Historical Data

The historical data trend for Progyny's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progyny Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

15.43

5.75

14.86

7.26

13.03

Progyny Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															3.59	14.53	13.05	14.26	10.00

Progyny ROCE % Calculation

Progyny's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	62.184	/	( ( (542.986 - 159.536)	+	(756.62 - 185.95) )	/ 2 )
	=	62.184	/	( (383.45	+	570.67)	/ 2 )
	=	62.184	/	477.06
	=	13.03 %

Progyny's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	55.2	/	( ( (726.512 - 193.419)	+	(756.62 - 185.95) )	/ 2 )
	=	55.2	/	( ( 533.093	+	570.67 )	/ 2 )
	=	55.2	/	551.8815
	=	10.00 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Progyny (NAS:PGNY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Progyny ROCE % Related Terms

Thank you for viewing the detailed overview of Progyny's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Progyny (Progyny) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Progyny Inc (NAS:PGNY) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1359 Broadway, New York, NY, USA, 10018

Website

https://www.progyny.com

Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.

Executives

David J Schlanger	director, officer: Executive Chairman	C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK NY 10018
Michael E Sturmer	officer: President	48 LEDYARD RD, WEST HARTFORD CT 06117
Mark S. Livingston	officer: Chief Financial Officer	C/O PROGYNY, INC., 1359 BROADWAY, 2ND FL, NEW YORK NY 10018
Kevin K Gordon	director	155 S LIMERICK RD, LIMERICK PA 19468
Tpg Gp A, Llc	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Peter Anevski	officer: Chief Executive Officer	C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK NY 10018
Cheryl Scott	director	800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Norman Payson	director	800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Allison Swartz	officer: EVP, GC	C/O PROGYNY, INC., 1359 BROADWAY, NEW YORK NY 10018
Lloyd H Dean	director	185 BERRY STREET, SUITE 300, SAN FRANCISCO CA 94107
Monice Barbero	officer: EVP, GC and Secretary	C/O PROGYNY, INC., 1359 BROADWAY, NEW YORK NY 10018
Jon Winkelried	10 percent owner	C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Beth C Seidenberg	director
Jennifer Bealer	officer: EVP, General Counsel	C/O PROGYNY, INC., 245 5TH AVENUE, NEW YORK NY 10016
Malissia Clinton	director	333 THREE D SYSTEMS CIRCLE, ROCK HILL SC 29730